Clinical Trials

87 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07621497 2026-06-02

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

229 enrolled

Colorectal Neoplasms

NCT07359456 2026-05-19

COLIBRI-GI

130 enrolled

Colorectal Neoplasms

NCT07543783 2026-04-28

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

38 enrolled

Carcinoma, Hepatocellular

NCT07420439 2026-04-27

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07535632 2026-04-17

BEST

58 enrolled

Colorectal Neoplasms

NCT07527858 2026-04-14

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

170 enrolled

Advanced Microsatellite Stable Colorectal Cancer

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07449481 2026-04-01

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

56 enrolled

CNS

Brain Neoplasms

NCT07497074 2026-03-27

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

78 enrolled

Uterine Cervical Neoplasms

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

180 enrolled

Colorectal Neoplasms

NCT07416058 2026-02-17

PHOENIX

61 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT07370818 2026-01-27

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

81 enrolled

Ovarian Neoplasms

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

20 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT07314619 2026-01-02

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

30 enrolled

Platinum-resistant Recurrent Ovarian Cancer (PROC)

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT07261709 2025-12-03

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

236 enrolled

Colorectal Neoplasms

NCT07244926 2025-11-24

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

31 enrolled

Lung Neoplasms

NCT07182708 2025-09-19

HOFIBREN

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT07150208 2025-09-02

THUMB

140 enrolled

Breast

Breast Cancer With Brain Metastasis

NCT07134101 2025-08-29

SMARTi-RC01

138 enrolled

Disease, Colorectal Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled

NSCLC

NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

47 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07123441 2025-08-14

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

300 enrolled

Colorectal Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

37 enrolled

Advanced Ovarian Cancer

NCT07106034 2025-08-12

ONTOP

32 enrolled

Colorectal Neoplasms

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

37 enrolled

mCRC

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT07070713 2025-07-17

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

44 enrolled

Metastatic Colorectal Cancer With Left-sided Primary Tumor

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Neutropenia, Colorectal Neoplasms

NCT07045805 2025-07-01

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

66 enrolled

Stomach Neoplasms

NCT07021950 2025-06-15

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

130 enrolled

Colorectal Neoplasms

NCT07014215 2025-06-10

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07007728 2025-06-06

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

54 enrolled

Colorectal Neoplasms

NCT07009145 2025-06-06

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

22 enrolled

Colorectal Neoplasms

NCT06872606 2025-03-12

SCRIPBOT

33 enrolled

Rectal Neoplasms

NCT06867432 2025-03-10

Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma

20 enrolled

Carcinoma, Hepatocellular

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06788171 2025-01-23

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

35 enrolled

Colorectal Cancer Liver Metastasis

NCT06683703 2024-11-12

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

118 enrolled

Non-small Cell Lung Cancer Patients with Brain Metastases

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer